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Patients with failed renal transplants represent an increasing
proportion of the current dialysis population. Although their
risk of anemia might be expected to be high, whether these
patients receive adequate anemia therapy after returning to
dialysis is unknown. We studied intravenous iron use, epoetin
doses, and hemoglobin levels in patients with and without
failed renal transplants who survived for 6 months after
initiation of dialysis in the United States between 1996 and
2001. Of the study population (n¼ 220 557), 9922 (4.5%) had
failed renal transplants. In spite of a greater likelihood of
receiving intravenous iron therapy (adjusted odds ratio (AOR)
1.47, Po0.0001) and epoetin (AOR 1.57, Po0.0001), patients
with failed transplants were more anemic and had higher
epoetin doses in each month of follow-up. During month 6,
patients with failed transplants were more likely to have
hemoglobin levels below 11 g/dl (AOR 1.50, Po0.0001) and
to have epoetin-to-hemoglobin ratios above the population
median of 1030 U/week per g/dl (AOR 1.73, Po0.0001).
Patients who return to dialysis with failed transplants are at a
higher risk of anemia than other patients who start dialysis;
the pattern of lower hemoglobin levels and higher ratios of
epoetin-to-hemoglobin suggests that relative epoetin
resistance may be contributory.
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Transplantation is the renal replacement therapy of choice for
most patients with end-stage renal disease. Long-term
mortality risks among patients receiving renal transplants
are estimated to be about one-third those of otherwise
similar dialysis patients remaining on the transplant waiting
list.1 Enhanced quality of life is another clear advantage of
renal transplantation.2–11 However, despite advances in the
field of renal transplantation, a substantial proportion of
patients experience progressive graft loss and return to
dialysis therapy. For example, recent estimates from the
United States Organ Procurement and Transplantation
Network show a 31.1% 5-year graft loss rate for
1998–2003.12 Approximately 7% of patients on maintenance
dialysis in the United States have had a failed renal
transplant.13
Anemia treatment guidelines for dialysis patients, such as
the National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines, do not differentiate
according to previous transplantation history.14 Patients with
failing renal transplants are often exposed to acute or chronic
inflammation, and to medications that suppress erythropoie-
sis; all things being equal, one might expect patients
returning to dialysis therapy with failing renal transplants
to show a greater predisposition to anemia than those
starting dialysis without previous transplantation. Surpris-
ingly, it is unknown whether patients with failed renal
transplants receive adequate anemia therapy after returning
to dialysis. The current study attempts to address this issue by
enumerating the prevalence of anemia in these patients and
investigating the time required to reach K/DOQI-recom-
mended hemoglobin levels.
RESULTS
We compared patients returning to dialysis with failed renal
transplants to incident dialysis patients with respect to
intravenous iron use, epoetin use, hemoglobin levels, and
epoetin dose. The study population included patients aged 18
years and older with Medicare as primary payer who began
or returned to dialysis between 1 January 1996, and 31
December 2001, and survived without transplantation for the
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following 6 months. Patients with failed transplants had an
interval of at least 1 year between transplantation and return
to dialysis.
During the study period, 38 325 patients aged 18 years and
older returned to dialysis with failed renal transplants. Of
these, 25 984 had Medicare as primary payer when they
returned to dialysis; of these, 21 476 had an interval of at least
1 year between transplantation and return to dialysis; and of
these, 9922 survived for 6 months without another kidney
transplant after returning to dialysis. Of the 338 147 patients
who began dialysis without prior transplantations, 260 111
had Medicare as primary payer when they began and of these,
210 635 survived for 6 months after beginning dialysis. The
study population (n¼ 220 557) thus included 9922 patients
with failed renal transplants and 210 635 with no prior
transplantations.
Table 1 compares characteristics of incident dialysis
patients with those of patients with failed renal transplants.
The discriminating characteristics of patients with failed
transplants include initiation of dialysis in later calendar
years, younger age, male sex, black race, and the absence of
each comorbid condition investigated. Table 1 also shows
that within 6 months of returning to dialysis, 64% of patients
with failed transplants received intravenous iron therapy and
82% received epoetin. The corresponding percentages were
marginally higher (Po0.001) for incident dialysis patients
Table 1 | Comparison of incident dialysis patients and patients with failed renal transplants










Incident dialysis patients 100 0 Reference Reference
Failed transplant patients 0 100 1.47 (1.40, 1.55) o0.0001 1.57 (1.48, 1.67) o0.0001
Received IV iron by dialysis month 6 67 64 o0.0001
Received epoetin by dialysis month 6 85 82 o0.0001
Year of dialysis
1996 16 14 Reference Reference
1997 16 15 1.44 (1.39, 1.48) o0.0001 1.15 (1.10, 1.20) o0.0001
1998 16 16 1.86 (1.80, 1.92) o0.0001 1.43 (1.37, 1.49) o00001
1999 17 17 1.83 (1.77, 1.89) o0.0001 1.29 (1.23, 1.34) o0.0001
2000 17 18 1.79 (1.74, 1.85) o0.0001 1.27 (1.22, 1.33) o00001
2001 18 19 o0.0001 3.05 (2.95, 3.16) o0.0001 1.96 (1.87, 2.05) o0.0001
Female sex 49 41 o0.0001 1.05 (1.03, 1.07) o0.0001 1.04 (1.01, 1.07) 0.0024
Age (years)
18–44 6 51 Reference Reference
45–64 19 41 1.25 (1.20, 1.30) o0.0001 1.04 (0.99, 1.09) 0.1173
X65 75 8 o0.0001 1.91 (1.84, 1.99) o0.0001 1.85 (1.77, 1.93) o0.0001
Race
White 68 61 Reference Reference
Black 27 35 1.16 (1.14, 1.19) o0.0001 1.09 (1.06, 1.12) o0.0001
Other/unknown 5 4 o0.0001 0.85 (0.81, 0.88) o0.0001 0.98 (0.93, 1.04) 0.4525
Comorbid conditions
Atherosclerotic heart disease 37 15 o0.0001 1.04 (1.01, 1.06) 0.0025 1.15 (1.11, 1.19) o0.0001
Congestive heart failure 44 21 o0.0001 1.17 (1.14, 1.20) o0.0001 1.35 (1.30, 1.40) o0.0001
Stroke or transient ischemic attack 12 5 o0.0001 0.99 (0.96, 1.02) 0.5481 1.15 (1.08, 1.21) o0.0001
COPD 17 7 o0.0001 1.13 (1.09, 1.16) o0.0001 1.22 (1.16, 1.28) o0.0001
Gastrointestinal bleeding 9 6 o0.0001 0.97 (0.94, 1.01) 0.0876 1.16 (1.09, 1.23) o0.0001
Diabetes mellitus 50 31 o0.0001 1.40 (1.37, 1.43) o0.0001 1.66 (1.61, 1.72) o0.0001
Hypertension 73 66 o0.0001 2.66 (2.60, 2.72) o0.0001 4.37 (4.24, 4.51) o0.0001
Infectious hospitalizations
0 62 61 Reference Reference
1–3 36 37 1.04 (1.02, 1.07) 0.0001 1.50 (1.44, 1.55) o0.0001
4 or more 2 2 0.0068 0.63 (0.59, 0.68) o0.0001 1.19 (1.05, 1.35) 0.0072
AOR, adjusted odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; i.v., intravenous.
aWith logistic regression, adjusted for incident dialysis or failed transplant, year of dialysis initiation, sex, race, and comorbid conditions.
bInteraction terms analysis showed that the following associations differed in patients with and without failed transplants: female (Po0.0001, AOR 0.87 with failed transplant,
1.06 without failed transplant), age 45–64 (P=0.0001, AOR 1.06, 1.30), hypertension (Po0.0001, AOR 2.11, 2.69), and the years 1997–2001 (all Po0.0001; AOR with failed
transplant 1.19, 1997; 1.40, 1998; 1.46, 1999; 1.45, 2000; 2.07, 2001; without failed transplant 1.45, 1997; 1.89, 1998; 1.85, 1999; 1.81, 2000; 3.12, 2001).
cInteraction terms analysis showed that the following associations differed in patients with and without failed transplants: age 45–64 (P=0.0142, AOR 1.19 with failed
transplant, 1.01 without failed transplant), other race (P=0.0296, AOR 0.75, 0.99), diabetes (P=0.0174, AOR 1.39, 1.67), hypertension (Po0.0001, AOR 3.14, 4.46), and the years
1998, 1999, and 2001 (Po0.0001, 1998; 0.0084, 1999; o0.0001, 2001; AOR with failed transplant 0.97, 1998; 0.996, 1999; 1.22, 2001; without failed transplant 1.46, 1998; 1.30,
1999; 1.99, 2001).
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with no prior transplants, of whom 67% received intravenous
iron therapy and 85% received epoetin. When adjustment
was made for year of dialysis initiation, sex, race, comorbid
conditions, and infectious hospitalizations, patients with
failed transplants were 1.47 times more likely than incident
dialysis patients to receive intravenous iron therapy and 1.57
times more likely to receive epoetin in the first 6 months after
returning to dialysis.
Figures 1 and 2 show hemoglobin levels and epoetin doses
for patients treated with epoetin in the first 6 months of
dialysis. Compared with incident dialysis patients with no
prior transplants, patients with failed transplants were more
anemic and had higher epoetin doses in each month of
follow-up. Table 2 shows multivariate associations of
hemoglobin levels o11 g/dl and epoetin-to-hemoglobin
ratios above the 6-month population median of 1030 U/
week per g/dl. When adjustment was made for year of dialysis
initiation, sex, race, comorbid conditions, and infectious
hospitalizations, patients with failed transplants were 1.50
times more likely than incident dialysis patients to have
hemoglobin levels o11 g/dl and 1.73 times more likely to
have epoetin-to-hemoglobin ratios 41030 U/week per g/dl
in month 6 of dialysis.
Other factors that could influence hemoglobin levels and
epoetin resistance within the transplant population (includ-
ing duration of graft survival, transplant nephrectomy after
the return to dialysis, and mode of immunosuppression)
were analyzed separately with models including only the
transplant group. Longer graft survival was associated with
receiving iron (adjusted odds ratio (AOR)¼ 1.16,
P¼ 0.0469) and a lower likelihood of hemoglobin o11 g/dl
(AOR¼ 0.82, P¼ 0.0188). Nephrectomy within 3 months of
returning to dialysis (16%) was associated with epoetin
(AOR¼ 2.12, Po0.0001) and iron (AOR¼ 1.62, Po0.0001)
use, a lower likelihood of hemoglobino11 g/dl (AOR¼ 0.73,
Po0.0001), and a high epoetin-to-hemoglobin ratio
(AOR¼ 1.35, Po0.0001).
For the subset of transplant patients for whom United
Network of Organ Sharing transplant follow-up forms could
be found (65% of 9922), the most recent follow-up form
before a graft failure was used to determine use of
corticosteroid (7%), calcineurin inhibitors (cyclosporine or
tacrolimus, 83%), azathioprine (34%), or mycophenolate
mofetil (36%). Using a model with the same adjustors as
above, only mycophenolate mofetil was associated with a
study outcome (a high epoetin-to-hemoglobin ratio,
AOR¼ 1.29, P¼ 0.0018).
Of patients with failed transplants, 5840 (59%) had
epoetin claims at month 12. Of these, 46% had hemoglobin
levels o11 g/dl at month 6 and at month 12, and 72% had
epoetin-to-hemoglobin ratios 41030 U/week per g/dl at
month 6 and at month 12. Among non-transplant patients,
127 802 (61%) had epoetin claims at month 12. Of these,
43% had hemoglobin levels o11 g/dl at month 6 and at
month 12, and 63% had epoetin-to-hemoglobin ratios
41030 U/week per g/dl at month 6 and at month 12.
DISCUSSION
Graft-failure patients have a higher mortality rate than
incident dialysis patients.15 When case-mix was taken into
account, we found that patients returning to dialysis after
failed renal transplantation were much more likely to start
therapy with intravenous iron and epoetin; nevertheless,
they were much less likely to attain K/DOQI hemoglobin
targets, and the observation of substantially higher epoetin-
to-hemoglobin ratios suggests that lower hemoglobin targets
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Figure 1 | Mean hemoglobin levels, dialysis months 1–6. Po0.001
for each month for the comparison of patients with and without
failed transplants. Hb, hemoglobin, in g/dl.




















































Figure 2 | Epoetin doses, dialysis months 1–6. Po0.001 for each
month for the comparison of patients with and without failed
transplants.
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Few studies have examined anemia management in
patients with failed renal transplants. Thus, a PubMed search
on 15 September 2006, using the terms transplant failure,
dialysis, hemoglobin, and epoetin yielded 21 citations, of
which only one was relevant to the question addressed in our
study. That report, by Almond et al.16 in 1994, was a cross-
sectional examination of epoetin doses in 60 dialysis patients.
Epoetin doses were approximately 70% higher in patients
with failed transplants than in patients with no prior
transplantation.
Anemia is relatively common in patients with functioning
renal transplants. One study of 4263 patients from 72 centers
in Europe17 reported that approximately one in three
transplant patients develops anemia (defined as hemoglobin
levels o13 g/dl in male and o12 g/dl in female subjects) at
some stage after engraftment. Impaired glomerular filtration
was the dominant association; other associations included
the use of angiotensin-converting enzyme inhibitors and
known myelosuppressant agents such as azathioprine and
mycophenolate, kidneys from older donors, and recent
infections. It is tempting to suggest that some of these
factors may have been involved in the apparent epoetin
resistance we observed in patients returning to dialysis with
failed transplants. Also, conceivably, ongoing chronic allo-
graft nephropathy and recurrence of a primary renal disease
of an inflammatory nature may account for some of our
findings.
Several limitations of our study should be noted. This was
a retrospective analysis using claims to define the study
subjects and their outcomes. The study entry criteria,
reflecting the twin pressures of wishing to study patients
immediately from inception of dialysis and reliance on
Medicare claims for longitudinal data points, produced a
subset of all patients returning to dialysis with failed
transplants. The available data did not allow us to determine
whether allograft loss was due to chronic allograft nephro-
Table 2 | Associations of hemoglobin o11 g/dl and epoetin-to-hemoglobin ratio 41030 at dialysis month 6
Hemoglobin o11 g/dl Epoetin/hemoglobin ratio 41030 units/week per g/dl
AORa,b 95% CI P AORa,c 95% CI P
Incident dialysis patients Reference Reference
Failed transplant patients 1.50 1.42, 1.59 o0.0001 1.73 1.63, 1.83 o0.0001
Year of dialysis
1996 Reference Reference
1997 0.98 0.95, 1.02 0.2793 0.99 0.95, 1.02 0.5086
1998 0.59 0.57, 0.61 o0.0001 1.21 1.17, 1.25 o0.0001
1999 0.47 0.45, 0.49 o0.0001 1.30 1.25, 1.34 o0.0001
2000 0.39 0.38, 0.41 o0.0001 1.21 1.17, 1.25 o0.0001
2001 0.34 0.33, 0.35 o0.0001 1.30 1.26, 1.35 o0.0001
Female sex 1.09 1.07, 1.12 o0.0001 1.00 0.98, 1.02 0.9994
Age (years)
18–44 Reference Reference
45–64 0.81 0.77, 0.85 o0.0001 1.01 0.96, 1.06 0.6402
X65 0.68 0.65, 0.71 o0.0001 0.83 0.79, 0.87 o0.0001
Race
White Reference Reference
Black 1.17 1.14, 1.20 o0.0001 1.36 1.33, 1.39 o0.0001
Other/unknown 1.07 1.02, 1.13 0.0067 0.84 0.80, 0.88 o0.0001
Comorbid conditions
Atherosclerotic heart disease 1.00 0.98, 1.02 0.9697 1.04 1.01, 1.06 0.0033
Congestive heart failure 1.04 1.02, 1.07 0.0017 1.14 1.11, 1.17 o0.0001
Stroke or transient ischemic attack 1.07 1.04, 1.11 o0.0001 0.98 0.95, 1.01 0.1192
COPD 1.05 1.03, 1.09 0.0003 1.02 0.99, 1.04 0.2393
Gastrointestinal bleeding 1.23 1.18, 1.27 o0.0001 1.30 1.26, 1.35 o0.0001
Diabetes mellitus 1.03 1.01, 1.05 0.0188 1.04 1.01, 1.06 0.0014
Hypertension 1.01 0.98, 1.04 0.4501 1.16 1.12, 1.19 o0.0001
Infectious hospitalizations
0 Reference Reference
1–3 1.24 1.22, 1.27 o0.0001 1.28 1.25, 1.31 o0.0001
4 or more 2.24 2.08, 2.43 o0.0001 1.54 1.43, 1.67 o0.0001
AOR, adjusted odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.
aWith logistic regression, adjusted for incident dialysis or failed transplant, year of dialysis initiation, sex, race, and comorbid conditions.
bInteraction terms analysis showed that the following association differed in patients with and without failed transplants: age 45–64 (P=0.0114, AOR 0.91 with failed
transplant, 0.78 without failed transplant) and four or more infectious hospitalizations (P=0.0130, AOR 1.47, 2.29).
cInteraction terms analysis showed that the following association differed in patients with and without failed transplants: female (P=0.0007, AOR 1.19 with failed transplant,
0.99 without failed transplant), one to three infectious hospitalizations (P=0.0161, AOR 1.12, 1.29), and four or more infectious hospitalizations (P=0.0032, AOR 0.93, 1.58).
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pathy, calcineurin nephrotoxicity, or recurrence of a primary
renal disease; which patients used fistulas, grafts, and
catheters for dialysis vascular access; or medication use,
historical and current. The hemoglobin levels of patients not
receiving epoetin were unknown. Iron store measures were
unavailable, as were standard indicators of nutritional
anemia, such as B12 and folate levels. Similarly, serological
measures of inflammatory and oxidative stress could not be
determined. Information on the route of epoetin application
was not available; however, current data from the Centers for
Medicare and Medicaid Services End-stage Renal Disease
Clinical Performance Measures Project show that less than
10% of epoetin is given subcutaneously.18
Despite its limitations, we believe this study has useful
features. The sample size is large and reflective of clinical
practice at a national level. On a relative basis, loss of renal
allograft function may be the most rapidly increasing cause of
end-stage renal disease requiring dialysis. As was apparent in
this study, patients with failed transplants are considerably
younger and healthier than the typical newcomer to dialysis
therapy. The possibility of a repeat transplant may be
considered in many of these patients. Suggesting that
hemoglobin targets should be similar in dialysis patients
with failed transplants and those with no prior transplants
seems reasonable. Our study suggests that current manage-
ment of anemia in patients with recently failed renal
transplants may be suboptimal.
MATERIALS AND METHODS
Patients
Patients with failed transplants were identified from the United
States Renal Data System (USRDS) data set, which incorporates data
from the United Network of Organ Sharing. These patients had the
following characteristics:
1. returned to dialysis between 1 January 1996, and 31 December
2001;
2. agedX18 years at transplant failure date;
3. had Medicare as primary payer at time of return to dialysis;
4. had X1 year interval between engraftment and return to
dialysis;
5. survived for 6 months after returning to dialysis.
Incident dialysis patients were identified from the USRDS data
set. They had the following characteristics:
1. initiated dialysis between 1 January 1996, and 31 December
2001;
2. agedX18 years at first dialysis service date;
3. had Medicare as primary payer at time of dialysis initiation;
4. survived for 6 months after initiating dialysis.
Measurements
Epoetin claims and associated hemoglobin levels in the first 6
months after dialysis initiation were identified from the USRDS data
set, using the following criteria:
1. hematocrit between 10 and 50%;
2. dose per epoetin administration between 500 and 80 000 U;
3. epoetin administrations between 1 and 20 per month.
We made an a priori decision that values outside these ranges
were more likely to represent claim error than clinical reality.
We also determined, on a monthly basis, whether intravenous
iron was used.
Analysis
We reasoned that 6 months after the start of dialysis therapy would
be a sufficient amount of time to establish clinical stability and to
gauge therapeutic approaches to anemia treatment. Accordingly, we
report findings on patients who survived for 6 months after the
initiation of dialysis. Our findings were very similar, however, when
6-month survival was not required. International Classification of
Diseases, Ninth Revision, Clinical Modification and Physicians’
Current Procedural Terminology codes were used to define comorbid
conditions and infectious hospitalizations, based on claims made in
the first 3 months of dialysis therapy. We used the w2 test to compare
proportions of patients with mean hemoglobin levels o10, 10 to
o11, 11 to o12, and X12 g/dl in each of the first 6 months after
initiation of dialysis therapy. In addition, we used logistic regression
to identify associations of intravenous iron use and epoetin use
among all patients, mean hemoglobin levels above 11 g/dl, epoetin
doses above the median, and epoetin-to-hemoglobin ratios above
the median in month 6. Finally, to determine whether associations
were similar in subgroups of patients with failed transplants and
with no prior transplantation, all associations in multivariate
analyses were repeated with interaction terms made between
candidate associations and the presence or absence of a failed
transplant.
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